Search Antibody Database

Found 1 matching record:

Displaying record number 3960

Download this epitope record as JSON.

MAb ID	HG129
HXB2 Location	gp160	gp160 Epitope Map
Author Location
Epitope
Ab Type	gp120 V3 // V3 glycan (V3g)
Neutralizing	No
Species (Isotype)	human(IgA)
Patient
Immunogen	vaccine
Country	Thailand
Keywords	cell-line isolated antibody, vaccine-induced immune responses

Vaccine Details

Vaccine type	RV144
Vaccine component	HIV-1

Notes

Showing 1 of 1 note.

HG129: Two native HIV-1 Env-specific IgA MAbs, HG129 and HG130, obtained from peripheral blood memory B cells of an RV144 vaccine recipient, were characterized for their ability to mediate antiviral activity in vitro. HG129 mediated monocyte phagocytosis and blocked HIV-1 Env glycoprotein binding to galactosylceramide, an alternative HIV-1 receptor, which may be effective host defense mechanisms at the mucosal portals of entry. This study elucidates potential antiviral functions of vaccine-elicited HIV-1 envelope-specific IgA that may act to block HIV-1 acquisition at the portal of entry. Wills2018 (vaccine-induced immune responses, cell-line isolated antibody)

References

Showing 1 of 1 reference.

Isolation Paper
Wills2018 Saintedym Wills, Kwan-Ki Hwang, Pinghuang Liu, S. Moses Dennison, Matthew Zirui Tay, Xiaoying Shen, Justin Pollara, Judith T. Lucas, Robert Parks, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayapan, Jaranit Kaewkungwal, Rasmi Thomas, Jerome H. Kim, Nelson L. Michael, Merlin L. Robb, Mike McRaven, David C. Montefiori, Thomas J. Hope, Hua-Xin Liao, M. Anthony Moody, Guido Ferrari, Barton F. Haynes, S. Munir Alam, Mattia Bonsignori, and Georgia D. Tomaras. HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. J. Virol., 92(7), 1 Apr 2018. PubMed ID: 29321320. Show all entries for this paper.